Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
BISPHOSPHONATES
DENOSUMAB
ONJ
OSTEONECROSIS OF THE JAW
OSTEOPOROSIS
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
05
11
2021
received:
18
08
2021
accepted:
09
11
2021
pubmed:
18
11
2021
medline:
15
3
2022
entrez:
17
11
2021
Statut:
ppublish
Résumé
Osteonecrosis of the jaw (ONJ) is a rare but serious adverse event associated with antiresorptive treatment. There is little evidence regarding the incidence of ONJ among patients with osteoporosis who are treated with denosumab versus bisphosphonates (BPs). The aim of this study was to determine the risk of ONJ in a real-world population. Subjects who underwent at least one dual-energy X-ray absorptiometry (DXA) examination were included in the osteoporosis register of the Swiss Society of Rheumatology between January 1, 2015, and September 30, 2019. Statistical analyses included incidence rates, rate ratios, and hazard ratios for ONJ, considering sequential therapies and drug holidays as covariates. Among 9956 registered patients, 3068 (89% female, median age 69 years [63 to 76]) were treated with BPs or denosumab for a cumulative duration of 11,101 and 4236 patient-years, respectively. Seventeen cases of ONJ were identified: 12 in patients receiving denosumab at the time of ONJ diagnosis and 5 in patients receiving oral or intravenous BP therapy. The diagnosis of ONJ was confirmed by independent and blinded maxillofacial surgeons, using the American Association of Oral and Maxillofacial Surgeons case definition of ONJ. The incidence of ONJ per 10,000 observed patient-years was 28.3 in patients receiving denosumab and 4.5 in patients with BP-associated ONJ, yielding a rate ratio of 6.3 (95% confidence interval [CI] 2.1 to 22.8), p < 0.001. Nine of 12 patients who developed ONJ during denosumab treatment had been pretreated with BPs, but none of the 5 patients with BP-related ONJ had previously received denosumab. The risk of ONJ was higher in patients receiving denosumab therapy compared with BPs (hazard ratio 3.49, 95% CI 1.16 to 10.47, p = 0.026). Previous BP therapy before switching to denosumab may be an additional risk factor for ONJ development. © 2021 American Society for Bone and Mineral Research (ASBMR).
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Denosumab
4EQZ6YO2HI
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
340-348Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021 American Society for Bone and Mineral Research (ASBMR).
Références
Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014;72(10), 1938-1956.
Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23.
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-1117.
Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.
Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D. Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo. 2017;69(1):9-15.
Grbic JT, Black DM, Lyles KW, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 2010;141:1365-1370.
Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-523.
Watts NB, Grbic JT, Binkley N, et al. Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years. J Clin Endocrinol Metab. 2019;104(6):2443-2452.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on bisphosphonate-related osteonecrosis of the jaw-2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2-12.
Hanley JA, Lippman HA. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA. 1983;249(13):1743-1745.
Eiken PA, Prieto-Alhambra D, Eastell R, Abrahamsen B. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. Osteoporos Int. 2017;28:2921-2928.
Tennis P, Rothman KJ, Bohn RL, et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf. 2012;21(8):810-817.
Ulmner M, Jarnbring F, Törring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg. 2014;72(1):76-82.
Khan AA, Rios LP, Sándor GKB, et al. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol. 2011;38(7):1396-1402.
Limones A, Sáez-Alcaide LM, Díaz-Parreño SA, Helm A, Bornstein MM, Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab vs. zoledronic acid: a systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020;25(3):e326-e336.
Jakob T, Tesfamariam YM, Macherey S, et al. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. Cochrane Database Syst Rev. 2020;12(12):CD013020.
Jiang L, Cui X, Ma H, Tang X. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials. J Orthop Surg Res. 2021;16(1):400.
Srivastava A, Nogueras Gonzalez GM, Geng Y, et al. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer. 2021;29(5):2305-2317.
Voss PJ, Steybe D, Poxleitner P, et al. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis. Odontology. 2018;106(4):469-480.
Yarom N, Lazarovici TS, Whitefield S, Weissman T, Wasserzug O, Yahalom R. Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(1):27-30.
Ikesue H, Doi K, Morimoto M, et al. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemother Pharmacol. 2021;87(6):871-877.
Loyson T, Van Cann T, Schöffski P, et al. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belgica Int J Clin Lab Med. 2018;73(2):100-109.
Ehrenstein V, Heide-Jørgensen U, Schiødt M, et al. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden. Cancer. 2021;127(21):4050-4058.
Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
Ottesen C, Schiodt M, Gotfredsen K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): a systematic review. Heliyon. 2020;6(4):e03795.
Hasegawa T, Hayashida S, Kondo E, et al. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study. Osteoporos Int. 2019;30(1):231-239.
Jung SY, Suh HS, Park JW, Kwon JW. Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw. Oral Dis. 2019;25(2):471-480.
Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.
Chang J, Hakam AE, McCauley LK. Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr Osteoporos Rep. 2018;16(5):584-595.
Kim SH, Lee YK, Kim TY, Ha YC, Jang S, Kim HY. Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: a nationwide cohort-study. Bone. 2021;143:115650.
Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence-what is it and what can it tell us? N Engl J Med. 2016;375(23):2293-2297.
Teoh L, Moses G, Nguyen AP, McCullough MJ. Medication-related osteonecrosis of the jaw-analysing the range of implicated drugs from the Australian database of adverse event notifications. Br J Clin Pharmacol. 2021;87(7):2767-2776.
Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review. J Cranio-Maxillofacial Surg. 2017;45(9):1493-1502.
Neha R, Beulah E, Anusha B, Vasista S, Stephy C, Subeesh V. Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals. Int J Clin Pharmacol. 2020;42(2):721-727.
Yuan A, Munz A, Reinert S, Hoefert S. Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;129(2):133-140.
Aoki K, Matsunaga S, Ito S, et al. Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis. J Bone Miner Metab. 2021;39(5):737-747.
Pichardo SEC, Broek FWT, Fiocco M, Appelman-Dijkstra NM, van Merkesteyn JPR. A comparison of the cone beam computed tomography findings in medication-related osteonecrosis of the jaws related to denosumab versus bisphosphonates: an observational pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;129(4):411-417.
Ikesue H, Mouri M, Tomita H, et al. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Support Care Cancer. 2021;29(8):4763-4772.
Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020:dgaa756. 106(1), 264-281.
Everts-Graber J, Reichenbach S, Gahl B, Ziswiler HR, Studer U, Lehmann T. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone. 2021;144:115830.
Burckhardt P, Faouzi M, Buclin T, Lamy O. Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res. 2021;36(9):1717-1728.
Ferrari S, Lewiecki EM, Butler PW, et al. Favorable skeletal benefit/risk of long-term denosumab therapy: a virtual-twin analysis of fractures prevented relative to skeletal safety events observed. Bone. 2020;134:115287.
Lerman MA, Xie W, Treister NS, Richardson PG, Weller EA, Bin WS. Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. Oral Oncol. 2013;49(9):977-983.
Lin TC, Yang CY, Kao Yang YH, Lin SJ. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. Osteoporos Int. 2014;25(5):1503-1511.